Combination therapy reduces risk of cancer recurrence

Thursday 19 January 2023


The Roche Group has reported the success of a combination therapy in reducing the risk of cancer recurrence in patients with early-stage hepatocellular carcinoma. A Phase 3 trial which combined the immune checkpoint inhibitor Tecentriq (atezolizumab) and Avastin (bevacizumab) and was administered as an adjuvant treatment after surgery, showed a statistically significant improvement in recurrence-free survival in patients at an increased risk of their disease returning.